Hair Relaxer Uterine Cancer
vs. L'Oréal / Revlon / Softsheen
NIH study links chemical hair relaxers to uterine cancer. Class action filed against major manufacturers for failing to warn consumers of cancer risk.
2022
filed
Accepting cases
Latest News & Updates
Latest Updates on Hair Relaxer Uterine Cancer
Check back soon for the latest news and updates on this case.
Articles & Resources
Understanding Your Rights in the Hair Relaxer Uterine Cancer Case
Learn what you need to know about eligibility, deadlines, and the claims process.
Settlement Distribution Timeline for Hair Relaxer Uterine Cancer
What to expect after a settlement is approved and how compensation is distributed.
FAQs: Common Questions About Hair Relaxer Uterine Cancer
Answers to frequently asked questions about eligibility, compensation, and the legal process.
Why You Should File Your Claim Before the Deadline
Understanding statute of limitations and why timing matters in class action lawsuits.
Frequently Asked Questions
Ready to Join This Case?
Connect with experienced class action attorneys who can evaluate your claim and guide you through the process. No upfront fees required.
Related Cases
Depo-Provera Brain Tumor (Meningioma)
Women who used Depo-Provera birth control injections developed intracranial meningioma brain tumors. French studies show 5.6x increased risk. Cases now being filed nationwide.
Paraquat Parkinson's Disease
Farmworkers and rural residents allege paraquat herbicide exposure caused Parkinson's disease. Thousands of cases pending in federal MDL.
Zantac / Ranitidine Cancer
Heartburn drug Zantac recalled after FDA found it contained NDMA, a probable carcinogen linked to bladder, stomach, and colon cancers.